Search

133 Result(s)
Sort by

Speak up

Speak up

We are committed to conducting business with integrity and in compliance with applicable laws, regulations, company policies and procedures.
The power of our people

The power of our people

Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
Taking cancer on with smart combinations

Taking cancer on with smart combinations

Boehringer Ingelheim digs deep into the science and taking a precision approach to develop smart combinations to bring the greatest benefit to patients.
Disentangling fibrosis

Disentangling fibrosis

Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Looking behind the scenes of Afrika Kommt!

Looking behind the scenes of Afrika Kommt!

Looking behind the scenes of Afrika Kommt! with Sabine and Eunice. I in D&I audio interview with reflections on a program designed to build bridges.
COVID-19: Research Update

COVID-19: Research Update

Boehringer Ingelheim stops treatment with experimental medication in study investigating benefits for severely ill patients with COVID-19
Our Vision

Our Vision

At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
EMPRISE

EMPRISE

Learn about the EMPRISE real-world evidence study and use of empagliflozin in routine clinical care
Advancing regenerative medicine

Advancing regenerative medicine

Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
Fighting Negative KRAS Feedback

Fighting Negative KRAS Feedback

Boehringer Ingelheim scientists are directly targeting KRAS, blocking feedback and ultimately getting ahead of resistance by investigating pan-KRAS approaches. Article from Marco Hofmann